Seeking Alpha

Advaxis cervical-cancer drug gets orphan designation

  • Advaxis' (ADXS) ADXS-HPV immunotherapy treatment for Stage II-IV invasive cervical cancer has received Orphan Drug Designation from the FDA.
  • ADXS-HPV has already generated encouraging Phase 2 data.
  • Shares are +8.5%. (PR)
Comments (1)
  • pagreen1966
    , contributor
    Comments (596) | Send Message
    One of the only good things about the recent biotech sell off was that the baby was thrown out with the bath water and excellent companies like (ADXS) were also hit hard giving us an excellent opportunity to buy the stock at bargain prices.


    Some very savvy analysts give this company a $10 price target over the next 12 months and that was before todays announcement!
    1 May, 09:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector